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Hyperlactatemia occurs during or after extracorporeal circulation in the form of lactic acido-
sis, increasing the risk of postoperative complications and the mortality rate. The aim of this
study was to evaluate whether continuous high-volume hemofiltration with volume replace-
ment through a polyethersulfone filter during the extracorporeal circulation procedure
decreases postoperative lactatemia and its consequences.
Materials and methods
This was a randomized controlled trial. Patients were randomly divided into two groups of
32: with or without continuous high-volume hemofiltration through a polyethersulfone mem-
brane. Five patients were excluded from each group during the study period. The sociode-
mographic characteristics, filter effects, and blood lactate levels at different times during the
procedure were evaluated. Secondary endpoints were studied, such as the reduction in the
intubation time and time spent in ICU.
Results
Lactatemia measurements performed during the preoperative and intraoperative phases
were not significantly different between the two groups. However, the blood lactate levels in
the postoperative period and at 24 hours in the intensive care unit showed a significant
reduction and a possible clinical benefit in the hemofiltered group. Following extracorporeal
circulation, the mean lactate level was higher (difference: 0.77 mmol/L; CI 0.95: 0.01–1.53)
in the nonhemofiltered group than in the hemofiltered group (p<0.05). This effect was
greater at 24 hours (p = 0.019) in the nonhemofiltered group (difference: 1.06 mmol/L; CI
0.95: 0.18–1.93) than in the hemofiltered group. The reduction of lactatemia is associated
with a reduction of inflammatory mediators and intubation time, with an improvement in liver
function.
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Conclusions
The use and control of continuous high-volume hemofiltration through a polyethersulfone
membrane during heart-lung surgery could potencially prevent postoperative complications.
The reduction of lactatemia implied a reduction in intubation time, a decrease in morbidity
and mortality in the intensive care unit and a shorter hospital stay.
Introduction
Lactate is a biomarker for which its increase or decrease can serve as a predictor of morbidity
and mortality in intensive care units (ICUs) [1]. Arterial lactatemia results from the produc-
tion and elimination of lactate molecules. The concentration of lactate in the body is generally
less than 2 mmol/L [2]. When there is a decrease in the supply of oxygen such as anemia or
low cardiac output, there is an increase in anaerobic metabolism with the conversion of pyru-
vate to lactate, increasing its concentration in the blood [3].
Lactate can also be synthesized in critical patients, especially in cases of cardiogenic shock,
acute respiratory failure, pneumonia, or sepsis [4, 5]. These pathologies, together with a decrease
in clearance due to renal or hepatic failure, contribute to an increase in lactate levels in patients.
Cardiac surgery is relevant due to its relationship with cardiac biochemical processes during
extracorporeal circulation (ECC), in which the presence of elevated lactatemia is a predictor of
postoperative outcomes [6]. In fact, levels higher than 4.4 mmol/L are related to an increased
stay in the ICU and general ward [7].
During ECC, an increase in myocardial and peripheral tissue lactate is demonstrated, asso-
ciated with impaired tissue oxygenation and early onset hyperlactation, probably due to accel-
erated anaerobic metabolism as a result of increased circulating epinephrine and
inflammatory proteins [3].
Hyperlactatemia is considered when the average blood lactate value exceeds 2 mmol/L [8].
Its occurrence during or after ECC increases postoperative complications, such as infections,
while its decrease in the first 24 hours is associated with a decreased mortality rate [9]. How-
ever, the occurrence of lactic acidosis during ECC is a complex phenomenon, depending on
factors such as duration or hemodilution and ECC time [10, 11]. It is an additional indepen-
dent risk factor that leads to poor postoperative outcomes. Without the possibility of adequate
elimination from the bloodstream, lactate can reach levels above 4 mmol/L, which are associ-
ated with an increased risk of postoperative morbidity including a higher rate of 30-day mor-
tality after cardiac surgery [8, 12–15].
Intraoperative lactate measurement is a reliable assessment performed by perfusionists to
monitor tissue perfusion during surgical procedures [16]. The objective of the ECC, in addi-
tion to eliminating excess liquid, is to eliminate toxic and pro-inflammatory substances. This
is a technique that improves hemodynamics, lung function, and hemostasis [16]. Although
this combined practice (conventional and modified ultrafiltrations) is considered a safe tech-
nique during ECC [17], some authors have associated conventional ultrafiltration with the
occurrence of intraoperative hyperlactatemia during the ECC procedure and recommend its
use only in situations where the patient suffers from renal failure, a positive fluid balance, poor
response to diuretics, or prolonged ECC (more than 120 minutes) [18].
Continuous high-volume hemofiltration with volume replacement is used throughout the
ECC procedure to achieve the benefits of both techniques. A polyethersulfone membrane is
used for the transfer of solutes by flow dragging and according to the pore size of the mem-
brane to achieve electrolyte and lactate purification. It is important to use solutions with a low
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lactate content to fill the circuits of the ECC pump. These compounds have a supraphysiologi-
cal rate of plasma acetate throughout the ECC process [19, 20], and even small concentrations
of acetate produce pro-inflammatory and cardiotoxic effects [21]. However, they are widely
used as priming solutions in ECC [22].
Therefore, the objective of our study was to evaluate whether continuous high-volume
hemofiltration with volume replacement through a polyethersulfone filter during the ECC
procedure decreases postoperative lactatemia and its consequences.
Primary hypothesis
Continuous high-volume hemofiltration with volume replacement by the use of a polyether-




A randomized controlled trial was conducted between June 2017 and February 2018 at the
Puerta del Mar University Hospital (Spain). No variations were made to the trial design or out-
comes after trial commencement. This paper uses a trial protocol and the guidelines for report-
ing parallel group randomized trials (CONSORT); see S1 Protocol and S1 Checklist. The
authors confirm that all ongoing and related trials for this drug/intervention are registered.
Sample size calculation
Consecutive sampling was performed; as patients met the inclusion criteria, they were selected
to participate in the study. To determine the sample size, the value of the variance of the
response variable was calculated in a reference group [18]. The basic response variable in our
study was the lactate elimination rate expressed in amount/unit of time. To determine the
sample, we assumed an alpha risk of 0.05, a power of 0.80, a clinically important minimum dif-
ference of 0.5, and a standard deviation in the outcome variable of 0.7. The need for a total of
64 participants was finally concluded.
Ethics
This research conformed to the principles described in the Declaration of Helsinki and was
approved prior to its initiation by the ethics committee (IRB) of the Puerta del Mar University
Hospital on December 2nd, 2016. All patients who participated in the study signed an
informed consent form.
Participants, recruitment, randomization, and treatment allocation
The inclusion criteria were patients without urgent clinical interventions, patients undergoing
extracorporeal circulation normothermic surgical procedures and patients who had a mini-
mum time before decannulation of more than 60 minutes (myocardial reperfusion completed,
unclamped aorta, and ECC completed). The exclusion criteria were patients who did not sign
the informed consent form, patients with previous renal or hepatic failure, and procedures
without ECC. Although some oral antidiabetic agents, such as metformin, may alter lactate lev-
els [23], patients with diabetes were not excluded from the study because the preoperative lac-
tate values of these patients were within the limits of normality.
For the patient recruitment, a previous interview was conducted 24 hours before the sur-
gery after the hospital admission; in this interview the patients were informed about the
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components of extracorporeal circulation, the hemofiltration technique, and the study over-
view; they were also informed that, although they had signed the informed consent, they could
refuse to participate in the study at any time. Recruitment began on September 1st, 2017 and
ended on February 28th, 2018.
The study was blinded to the patients, data analysts, and ICU staff. The allocator randomly
divided the patients into a control group (CG) or a hemofiltered group (HG). In the HG a
polyethersulfone filter was used throughout the ECC while in the CG conventional procedures
without hemofiltration were used. Surgeries were randomly assigned to four groups: 44 cases
of valvular surgery (68.75%), 9 cases of coronary surgery (14.06%), 6 cases of valvular and cor-
onary surgery (9.38%), and 5 cases of aortic and ascending aortic replacement surgery (with
the Bentall technique) (7.81%).
The allocator was assigned by the head of the hospital’s ethics committee. He randomly
assigned patients into eight blocks, all being equivalent in all procedures except in the treat-
ment maneuvers; there were no notable differences between the possible confounders mea-
sured in the two analyzed groups. There was no stratification.
Procedure
In the present study, all patients were operated on under propofol-induced general anesthesia
and maintained during the procedure with the volatile anesthetic agent sevoflurane, including
during the ECC period. All procedures were performed through a median sternotomy, and
normothermia (309.15 K; 36˚C; 96.8˚F) was maintained in all patients throughout the
procedure.
An ECC open circuit consisting of a set of polyvinyl chloride tubes and a polypropylene
membrane oxygenator with an integrated arterial filter with a coating based on phosphoryl-
choline molecules was used. The ECC device consisted of a biopump, and all procedures were
performed with a centrifugal pump. In HG, the hemofiltration membrane used was a mem-
brane made of polyethersulfone, with a surface area of 1.35 m2.
The priming solution used contained (1) 80 mg dexamethasone, (2) 50 mg ranitidine, (3)
150 IU/kg sodium heparin, (4) 500 mL of a solution containing 40 mg/mL succinylated gela-
tine, and (5) 900 mL comprising 2 mmol/L of K+, 32 mmol/L of HCO3-, 111.5 mmol/L of Cl-,
140 mmol/L of Na+, 0.5 mmol/L of Mg2+, 1.75 mmol/L of Ca2+, 6.1 mmol/L of glucose, 3
mmol/L of lactate, and 250 mL of mannitol 20%.
The cardioplegia solution and procedure used in the surgical procedure was a modification
of that developed by Calafiore et al. [24], and the cardioplegia solution was administered ante-
grade through the aortic artery and retrograde through the coronary sinus. For this purpose,
80 mEq of KCl and 1.5 grams of MgSO4 were mixed in a 50 cm
3 syringe using a volumetric
infusion pump connected to the circuit through a three-step key.
The data were collected with a CONNECT1 system (LivaNova Deutschland, Münich, Ger-
many). To measure lactate levels, a GEM premier 40001 analyser was used, with amperomet-
ric biosensors connected to the ECC pump and a recording system for further statistical
analysis [25, 26]. The blood flowed from the oxygenator to the hemofilter through a recircula-
tion line with a flow of 100 to 500 mL/min, depending on the time of surgery, without exceed-
ing the maximum transmembrane pressure of 500 mmHg as recommended by the
manufacturer. The effluent rate was 110 ml/min to an average of 80 ml/kg/h, similar to HERO-
ICS study [27].
The HG was subjected to high-volume hemofiltration together with replacement of the
hemofiltered liquid with a solution used in extrarenal purification techniques comprising 2
mmol/L of K+, 32 mmol/L of HCO3-, 111. 5 mmol/L of Cl-, 140 mmol/L of Na+, 0.5 mmol/L of
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Mg2+, 1.75 mmol/L of Ca2+, 6.1 mmol/L of glucose, and 3 mmol/L of lactate. Pursuing a zero
balance, this solution allows for the replacement of 3,000 cm3 per hour with a maximum of
60,000 cm3/day.
Data analysis
The studied variables included biometric and analytical data that were analyzed preoperatively
(age, sex, height, weight, and EuroSCORE), intraoperatively (diuresis, time of clamping, time
of ECC, and attendance time between unclamping of the aorta and the completion of ECC),
and post-operatively at 24 hours after surgery or thereafter (time of use of inotropic agents, C-
reactive protein, intubation time, and time spent in ICU). Lactate and hemoglobin levels were
measured at all stages up to 24 hours after surgery. In the HG group, ultrafiltration was per-
formed from the beginning of ECC to the end. Blood samples were collected prior to initiation
of ECC; every 20 minutes during the procedure, with the highest value recorded; at the end of
the ECC; and 24 hours after admission to the ICU.
The units of the variables were: Age (years), sex (male/female), height (cm), weight (kg),
EuroSCORE (1–6 points), diuresis (cm3), time of clamping (minutes), time of ECC (minutes),
attendance time between unclamping of the aorta and the completion of ECC (minutes), lac-
tate (mmol/L), hemoglobin (g/dL), time of use of inotropic agents (hours), C-reactive protein
(mg/L), intubation time (hours), and time spent in ICU (days).
The parameters of oxygen supply, oxygen consumption, venous oxygen saturation and oxy-
gen extraction were continuously recorded throughout the procedure [28]. After hemody-
namic and respiratory stability with effective cough and neurological stability, spontaneous T-
tube ventilation was initiated. If the patient’s stability persisted, extubation was performed
[29]. These variables and procedures have allowed us to study secondary endpoints, including
possible benefits in patients with renal failure and the reduction in the intubation time, time
spent in ICU and C-reactive protein levels.
Quantitative variables were expressed by arithmetic means and standard deviations, or
medians and interquartile ranges. Qualitative variables were expressed as frequencies and per-
centages. The normality of continuous variables was evaluated with the Kolmogorov-Smirnov
test. For the analysis of intergroup changes, the following analyses were performed: ANO-
VA-RM test with a post hoc least significant difference (LSD) test, Student’s t-test to evaluate
the difference between the means of two independent groups, and the Mann-Whitney U test
for nonnormally distributed variables. To evaluate the statistical independence of the categori-
cal variables, the chi-square test was used. Statistical significance was considered at p<0.05.
Results
Of the 64 patients enrolled in this study, 32 were randomly assigned to each group (CG and
HG). During the assignment process, the following patients were excluded from the CG: 1 due
to the need for ventricular assistance at the end of ECC [30] and 4 for hemofiltration due to
preoperative anemia. In the HG, 3 of the patients were excluded from the study due to bleed-
ing that resulted in a new intervention within 24 hours after surgery, 1 was excluded due to
mediastinitis requiring a prolonged stay in the ICU, and 1 was excluded due to death from
intraoperative vasoplegia without response to vasoactive drugs. Fig 1 demonstrates the flow of
participants throughout the trial.
Participant characteristics
Table 1 shows the descriptive results of the sociodemographic, anthropometric and biochemi-
cal variables analyzed in both groups. With respect to the sex of the patients studied, there
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Fig 1. Study flow chart (CONSORT).
https://doi.org/10.1371/journal.pone.0242411.g001
Table 1. Comparative analysis of sex, age, height, weight, and serum lactate prior to the initiation of ECC between
the HG and CG.
Variables Total (N = 54) Group
CG (n = 27) HG (n = 27)
Sex:
Male 66.7% (36) 77.8% (21) 55.6% (15)
Female 33.3% (18) 22.2% (6) 44.4% (12)
Age (years) 63.30 (11.1) 62.81 (11.6) 63.78 (10.8)
Height (cm) 165.59 (10.5) 167.41 (8.7) 163.78 (11.8)
Weight (kg) 79.35 (15.4) 79.13 (15.2) 79.57 (15.9)
https://doi.org/10.1371/journal.pone.0242411.t001
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were 36 (66.7%) men and 18 (33.3%) women. The mean age of the total sample was 63.3 years
(CI: 0.95: 60.3–66.3; SD 11.1).
Patients’ hemodynamics
Previous average hemoglobin was 12.43 g/dL (CI: 0.95: 11.93–12.92; SD 1.82). Levels dropped
to a minimum of 8.28 g/dL during ECC (CI: 0.95: 7.88–8.67; SD 1.45), rising to 10.49 g/dL
after ECC (CI: 0.95: 7.35–13.63; SD 11.50) and averaging 10.70 g/dL (CI: 0.95: 10.27–11.12; SD
1.56) 24 hours after admission to the ICU. There were no significant differences between HG
and CG in all hemoglobin measurements collected during the study.
In the total of the participants, the time of use of inotropics has been distributed in the
range between 0 and 336 hours, with a median of 24 hours. The mean time is 45.85 h (CI: 0.95:
27.22–64.48; SD 68.26). Dividing the sample into the groups according to the hemofiltrate, it is
observed that the use of inotropic drugs is not normally distributed (p<0.000 in Kolmogorov-
Smirnov test). The mean value of cases with filter (49.85 hours) is somewhat higher than the
mean value of patients who have not had filter (41.85 hours). But this difference is not statisti-
cally significant (ZU = 0.04; p = 0.972).
By segmenting according to the EuroSCORE risk grades of the patients, the results indicate
that in the group of low risk patients, the difference in the time of use of inotropics is high.
Therefore, in this case, even having also high variability in the CG and the reduced number of
low risk patients in the EuroSCORE, the difference becomes statistically significant (p = 0.02).
Furthermore, the size of the effect (very large: 51.5%) supports the existence of this relation-
ship, according to which the time of use of inotropics is higher in the CG (Table 2). In addi-
tion, attendance time between unclamping of the aorta and the completion of ECC is less
variable and is reduced in low-risk EuroSCORE HG patients, so hemodynamic parameters
remain more stable than in the same EuroSCORE in CG (ZU = 2.32; p = 0.02). There are no
significant differences in the rest of the patients with medium and high EuroSCORE risk about
variables time of use of inotropic agents and attendance time between unclamping of the aorta
and the completion of ECC.
Lactate levels
Lactate measurements were performed by perfusionists at baseline, during ECC (the maxi-
mum value was considered), post-ECC, and at 24 hours in each group. In both groups, there
was a clear elevation in the mean values obtained during and after ECC as well as at 24 hours
with respect to the reference values. The differences between the measurements were signifi-
cant (p<0.001), with an effect size of 30.6% in the CG and 37.1% in the HG.
When the initial lactate measurement was excluded and the comparison was made with
only the latter three measurements (maximum during ECC, post-ECC, and at 24 hours), the
analysis showed two results. First, the CG retained statistical significance, but the effect size
was reduced to 12.7%, which is moderate-high. Second, there were no significant overall dif-
ferences in the HG (mild effect of 4.1%). As such, in both groups, these results clearly
Table 2. Intergroup inferential analysis. Comparison of the averages of the Inotropic Time (hours) between CG and HG and according to the EuroSCORE.
EuroSCORE CG (n = 27) HG (n = 27) t-test R2
n Mean (SD) n Mean (SD) Value p
Low risk group (n = 8) 4 94.50 (72.40) 4 3.00 (2.45) ZU = 2.32 0.020 0.515
Medium risk group (n = 23) 10 25.10 (44.62) 13 50.23 (88.32) ZU = 1.33 0.184 0.031
High risk group (n = 23) 13 42.23 (40.58) 10 63.30 (91.50) ZU = 0.16 0.876 0.026
https://doi.org/10.1371/journal.pone.0242411.t002
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demonstrated that the differences between the previous value and the latter three were signifi-
cant (p<0.001), with the previous value being lower than all the others. Likewise, in the HG
the values of these three measures did not differ significantly from each other, whereas in the
CG lactate increased significantly from the maximum ECC value to the post ECC (p<0.01)
and 24-hour values (only p<0.05 due to the high variability in this measurement). Between
these last two measurements (after ECC and 24 hours), the difference was no longer significant
(Table 3).
Regarding the analysis between groups (Table 4), the results show that there is also no sta-
tistically significant difference between the mean values of maximum lactate in ECC. However,
from there on, significant differences already appear. At the post-ECC moment, the mean lac-
tate value is higher (difference: 0.77 mmol/L; IC 0.95: 0.01–1.53) in CG (p = 0,047) although
with moderate effect (7.4%). The 24-hour mean lactate value is even higher (p = 0.019) in CG
(difference: 1.06 mmol/L; IC 0.95: 0.18–1.93).
Finally, an intergroup analysis was performed on different parameters. Statistical signifi-
cance was found for intubation time, and there was a noticeable difference in the length of stay
in the ICU between the two groups. The length of stay in the ICU was lower in the HG than in
the CG.
Table 3. Intragroup variation in the lactate values according to the time of measurement. Contrasts between pairs of measurements (LSD test) and overall contrast
(ANOVA-MR).
Measurement CG (n = 27) HG (n = 27)
Mean (SD) Previousd Max. ECCe Post-ECCf 24 hg Mean (SD) Previousd Max. ECCe Post-ECCf 24 hg
Previousd 1.01 (0.47) — 0.000 0.000 0.000 0.84 (0.27) — 0.000 0.000 0.000
Max. during ECCe 1.86 (1.06) 4.50c — 0.007 0.011 1.65 (0.45) 10.50c — 0.207 0.080
Post-ECCf 2.70 (1.57) 5.54c 2.30c — 0.646 1.93 (1.18) 5.04c 1.30 — 0.872
24 h 2.95 (2.12) 4.82c 2.72b 0.46 — 1.89 (0.80) 7.04c 1.82 0.16 —
ANOVA-RMa F = 11.46; p = 0.000; R2 = 0.306 ANOVA-RMa F = 15.33; p = 0.000; R2 = 0.371
Linear test F = 32.87; p = 0.000; R2 = 0.558 Linear test F = 49.29; p = 0.000; R2 = 0.655
Quadratic test F = 1.11; p = 0.301; R2 = 0.041 Quadratic test F = 11.62; p = 0.002; R2 = 0.309
aRepeated measures ANOVA.
bSignificant difference at 5% (p<0.05).
cHighly significant difference at 1% (p<0.01).
dPreoperative level.
eMaximum value in ECC.
fImmediately after ECC.
gAfter 24 hours of ECC.
https://doi.org/10.1371/journal.pone.0242411.t003
Table 4. Intergroup inferential analysis. Comparison of lactate means between CG and HG, at each measurement time.
Time CG (n = 27) HG (n = 27) t-test R2
Mean (SD) Mean (SD) Value p
Previousa 1.01 (0.47) 0.84 (0.27) 1.59 0.117 0.047
Max. during ECCa 1.86 (1.06) 1.65 (0.45) 0.94 0.349 0.017
Post-ECCb 2.70 (1.57) 1.93 (1.18) 2.04 0.047 0.074
24 h 2.95 (2.12) 1.89 (0.80) 2.43 0.019 0.102
aPreoperative level.
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The relationship between this time factor and the lactate levels was not the same in each
group. In the CG, the only possible relationship between these two variables was a direct linear
relationship (p<0.001; R2 = 55.8%). In the HG, although the most likely relationship was also
linear (p<0.001; R2 = 65.5%), the decrease in the last measurement indicated a quadratic-type
association (p<0.01; R2 = 30.9%).
The mean values of the arms are similar with a small difference of 8.5 minutes. The time in
CG being higher, although the difference does not reach statistical significance. There is no dif-
ference in the use of blood transfusions between the two groups.
The intubation time variable is not normally distributed (p<0.001 in the Kolmogorov-
Smirnov test) due to a large asymmetry with accumulation of cases in the low values versus
very few with high values. The total mean is 6.48 (CI 0.95: 5.13–7.84) with a median of 5 in a
range of 1 to 31 hours. Using the Mann-Whitney U-test, statistically significant differences
were found (p<0.05) so that according to the data of the averages (both mean and median) the
time is somewhat higher (about 3 hours) in CG. The effect size equivalent to this significance
is moderate (8.6%).
The time spent in ICU is also not normally distributed (p<0.01 in the Kolmogorov-Smir-
nov test) due to the concentration of cases in the low values as in the previous one. The mean
time of the total group is 4 days (CI 0.95: 3.33–4.74) and the mean values (mean and median)
of both groups are very similar to each other.
There is no statistical significance between groups in renal failure. Actually, the number of
cases with renal failure is very small, that in spite of the observed difference, this result must be
taken with caution and is not sufficient statistical evidence to be able to intuit an effect.
C-reactive protein is normally distributed with an average value of 81.69 mg/dL (IC 0.95:
71.53–91.85). The mean value of CG is slightly higher than the mean value of HG but this dif-
ference does not reach the statistical significance so our data does not allow us to admit that
the filter use factor is statistically related to C-reactive protein values (Table 5).
Discussion
Several authors have identified preoperative factors that favor the onset of hyperlactatemia
during ECC [13]. Patients with type II diabetes mellitus often increases lactate associated with
reduced aerobic oxidative capacity and restricted lactate transport. There are also factors that
associate the increase in lactate concentration with age, sex, and comorbidities. Anemia is
another factor associated with hyperlactatemia by decreasing oxygen supply and producing tis-
sue hypoxia even with normal intravascular volume [31, 32].
However, there are other mechanisms responsible for the appearance of hyperlactatemia in
the intraoperative period of cardiac surgery with ECC: (1) the duration of surgery with ECC,
with a relationship directly proportional to the time of surgery [10, 33], and (2) a deficit in
Table 5. Intergroup inferential analysis. Effect of filter use on different parameters.
Variables Total (N = 54) CG (n = 27) HG (n = 27) Contrast test R2
Value p
Time of ECC (minutes) 99.87 (44.82) 104.11 (51.94) 95.63 (36.87) t = 0.69 0.492 0.009
Blood transfusion (Yes) 22.2% (12) 22.2% (6) 22.2% (6) Chi2 = 0.00 1 ————
Intubation time (hours) 6.48 (4.96) 7.93 (6.38) 5.04 (2.30) ZU = 2.29 0.022 0.086
Time spent in ICU (days) 4.04 (2.59) 4.11 (1.74) 3.96 (3.26) ZU = 1.82 0.069 0.001
Renal failure (Yes) 9.3% (5) 14.8% (4) 3.7% (1) Chi2 = 1.98 0.159 0.040
C-reactive protein (mg/L) 81.69 (37.21) 85.08 (42.03) 78.30 (32.13) t = 0.67 0.509 0.008
https://doi.org/10.1371/journal.pone.0242411.t005
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oxygen intake and consumption as well as an increase in its extraction [28] as they affect the
morbidity of these patients, especially when lactate levels are higher than 4 mmol/L [7].
Nonetheless, the results obtained show that high-volume hemofiltration pursues a zero bal-
ance at the end of ECC, managing to mitigate the presence of high amounts of lactate regard-
less of sex and previous pathologies in patients during the preoperative period as well as the
duration of ECC.
In the context of this background, it was important to assess the difference between the two
studied groups; in the preoperative period, the elevation of lactate in the HG from ECC until
the last analysis at 24 hours had no significance (p>0.05). However, there was a significant
increase in the CG (p<0.01), which was independent of the time of ECC.
We must emphasize that in our study at all temporal points the optimal values of oxygen
contribution, consumption, and extraction were maintained because gases and the lactate levels
were measured to control pH and oxygenation. Even so, hyperlactatemia appeared during and
after ECC, probably due to alterations in microcirculation [3]. However, the level of hyperlacta-
temia was lower in the HG than in the CG, contrary to what Soliman et al. reported [18]; this is
possibly attributable to the low concentration of lactate in the extracorporeal circuit priming
solution used in this study (3 mmol/L) compared with that in Ringer’s solution (27 mmol/L).
It is important to highlight the time period from ECC departure until 24 hours after sur-
gery. In the CG, lactate continued to rise; however, in the HG, the reverse occurred. This qua-
dratic association can be attributed to a reduced need for clearance of lactate by the kidneys
and liver, thus improving liver function [34, 35]. This theory is also supported by the fact that
in postoperative patients who underwent cardiac surgery with ECC, increased lactate in the
absence of dysoxia can be caused by an exacerbated inflammatory response, mitigated by the
use of continuous high-volume hemofiltration with a polyethersulfone filter [36], thus result-
ing in a zero balance at the end of the procedure [37].
The results obtained in this study showed a decreased lactate level in the HG during ECC,
at the end of ECC, and 24 hours after surgery. The HG did not show significant changes in
contrast to the CG, possibly due to the permeability of the polyethersulfone membrane. This
membrane has a lactate screening coefficient equal to 1; thus, the concentration of lactate
obtained in the effluent is equal to that existing in the plasma.
Lactate elevation in the intra- and postoperative periods is due to complex mechanisms
rather than a single cause [38, 39], just as not all patients develop it in the same way. A number
of mechanisms can be involved during ECC, such as low oxygen supply [40] and prolonged
ECC time [41]. Currently, lactate deficit clearance in postoperative patients has been demon-
strated to be an independent risk factor for poor outcomes in postoperative cardiac surgery
with ECC patients [42].
On the other hand, lactate levels greater than 3 mmol at 6 hours after surgery increase the
probability of major complications [14, 43]. Therefore, these results suggest prove that in both
group, lactate varied significantly depending on the condition/time at which the measurement
was performed.
As for secondary outcomes, the use of inotropic agents in the postoperative period in rela-
tion to EuroSCORE indicates that low risk patients (0–2 points) benefit more from the tech-
nique of continuous hemofiltration with volume replacement, as non-hemofiltrators require a
longer time of use of inotropes. In fact, according to a recent study, the increased time of use
of inotropes implies an increased risk of morbidity and mortality after cardiac surgery [44]. In
the same way, the study shows that there is an improvement in the hemodynamic stability of
hemofiltrated patients at low risk in the EuroSCORE due to a shorter attendance time. How-
ever, these results should be interpreted with caution due to the low number of patients
included in this category of the EuroSCORE.
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Lactate reduction decreases mechanical ventilation time of patients undergoing cardiac sur-
gery with ECC. The length of stay in the ICU was also significantly reduced as a postoperative
intubation time greater than 12 hours is directly related to an increased length of stay [45].
Moreover, it prevents the appearance of high lactate levels caused by long stays in the ICU [46,
47]. This result is due to the use of hemofiltration and extracorporeal circuit priming solution
[48].
The use of intraoperative hemofiltration may be beneficial to the patient in the short term
as well as to patients with preoperative renal dysfunction in the long term [49]. Additionally, it
may also be recommended for patients with previous liver disease [36].
Strengths and limitations
In some countries, perfusionists collaborate with surgeons and anesthetists to control and
maintain ECC in patients before, during, and after surgery. The findings of this study involve a
series of interventions in clinical perfusionist practice to eliminate the increase in serum lactate
in surgical interventions with ECC and thereby reduce intubation time and morbidity and
mortality in the ICU as well as improved liver function.
The main limitation of this study was a lack of previous research on continuous high-vol-
ume hemofiltration with volume replenishment during ECC, preventing proper comparisons
with other studies. Moreover, more research focusing on these results with an equal or greater
sample of participants in this study is needed to obtain more consistent results.
Other limitations were the variability in the surgical procedures, the interventions by differ-
ent surgeons during the procedure that could have affected the time of surgery, the time of
ECC and the different medical and nursing teams during the postoperative period in the ICU
[11]. In addition, there are currently no analytical determinations that can discern the type of
hyperlactatemia that patients develop. However, this study aimed to reduce hyperlactatemia
regardless of its origin.
Conclusions
Although the occurrence of hyperlactatemia is common at the end of the ECC procedure, pro-
tocols aimed at reducing intra- and postoperative lactate levels through continuous high-vol-
ume hemofiltration with volume replacement and a zero balance favor the elimination of
lactate during the ECC procedure. This is reflected in the lactate levels at the end of ECC and
at 24 hours. The serum lactate levels in patients after ECC are decreased when continuous
high-volume hemofiltration with a polyethersulfone membrane is used. The reduction in lac-
tate levels within 24 hours after ECC in the CG was related to a decreased concentration of
serum lactate after ECC, allowing improved purification. Moreover, these results could poten-
tially stabilize the hemodynamics in low cardiac risk patients. This study could be fundamental
to establishing specific protocols for its use in cardiac surgery with ECC, which, in combina-
tion with postoperative nursing care, could shorten the duration of care of individuals under-
going this type of intervention.
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Abellán-Hervás, Ana-Marı́a Sáinz-Otero.
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17. Pérez-Vela JL, Ruiz-Alonso E, Guillén-Ramı́rez F, Garcı́a-Maellas MT, Renes-Carreño E, Cerro-Garcı́a
M, et al. ICU outcomes in adult cardiac surgery patients in relation to ultrafiltration type. Perfusion.
2008; 23: 79–87. https://doi.org/10.1177/0267659108095167 PMID: 18840575
18. Soliman R, Fouad E, Belghith M, Abdelmageed T. Conventional hemofiltration during cardiopulmonary
bypass increases the serum lactate level in adult cardiac surgery. Ann Card Anaesth. 2016; 19: 45.
https://doi.org/10.4103/0971-9784.173019 PMID: 26750673
19. Morgan TJ, Power G, Venkatesh B, Jones MA. Acid-Base Effects of a Bicarbonate-Balanced Priming
Fluid during Cardiopulmonary Bypass: Comparison with Plasma-Lyte 148. A Randomised Single-
Blinded Study. Anaesth Intensive Care. 2008; 36: 822–829. https://doi.org/10.1177/
0310057X0803600611 PMID: 19115651
20. Weinberg L, Chiam E, Hooper J, Liskaser F, Hawkins AK, Massie D, et al. Plasma-Lyte 148 vs. Hart-
mann’s solution for cardiopulmonary bypass pump prime: a prospective double-blind randomized trial.
Perfusion. 2018; 33: 310–319. https://doi.org/10.1177/0267659117742479 PMID: 29144182
21. Davies PG, Venkatesh B, Morgan TJ, Presneill JJ, Kruger P, Thomas BJ, et al. Plasma acetate, gluco-
nate and interleukin-6 profiles during and after cardiopulmonary bypass: a comparison of Plasma-Lyte
148 with a bicarbonate-balanced solution. Crit Care. 2011; 15: R21. https://doi.org/10.1186/cc9966
PMID: 21235742
22. Miles LF, Coulson TG, Galhardo C, Falter F. Pump Priming Practices and Anticoagulation in Cardiac
Surgery. Anesth Analg. 2017; 125: 1871–1877. https://doi.org/10.1213/ANE.0000000000002052
PMID: 28614119
23. Kuan IHS, Savage RL, Duffull SB, Walker RJ, Wright DFB. The Association between Metformin Ther-
apy and Lactic Acidosis. Drug Saf. 2019 [cited 19 Oct 2019]. https://doi.org/10.1007/s40264-019-
00854-x PMID: 31372935
24. Calafiore AM, Teodori G, Mezzetti A, Bosco G, Verna AM, Di Giammarco G, et al. Intermittent ante-
grade warm blood cardioplegia. Ann Thorac Surg. 1995; 59: 398–402. https://doi.org/10.1016/0003-
4975(94)00843-v PMID: 7847955
25. Ottens J, Baker RA, Newland RF, Mazzone A. The future of the perfusion record: automated data col-
lection vs. manual recording. J Extra Corpor Technol. 2005; 37: 355–359. PMID: 16524151
26. LivaNova. Connect system. 2017 [cited 12 August 2020]. In: Connect [Internet]. London: LivaNova—
[about 3 screens]. Available from: https://www.livanova.com/en-US/Home/Products-Therapies/
Cardiovascular/Healthcare-Professionals/Cardiopulmonary/Data-Management-Systems/Connect.
aspx.
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